<bill session="116" type="h" number="4244" updated="2022-11-01T13:50:07Z">
  <state datetime="2019-09-09">REFERRED</state>
  <status>
    <introduced datetime="2019-09-09"/>
  </status>
  <introduced datetime="2019-09-09"/>
  <titles>
    <title type="display">MAGIC Act</title>
    <title type="display">MAGIC Act</title>
    <title type="official" as="introduced">To provide for a pathway for chemically synthesized insulin to be approved under an abbreviated new drug application submitted under the Federal Food, Drug, and Cosmetic Act, and for other purposes.</title>
    <title type="short" as="introduced">MAGIC Act</title>
    <title type="short" as="introduced">Market Access for Generic Insulin Competition</title>
  </titles>
  <sponsor bioguide_id="K000376"/>
  <cosponsors>
    <cosponsor bioguide_id="F000466" joined="2019-12-23"/>
    <cosponsor bioguide_id="K000395" joined="2020-02-04"/>
    <cosponsor bioguide_id="P000605" joined="2019-12-23"/>
    <cosponsor bioguide_id="T000467" joined="2019-12-23"/>
  </cosponsors>
  <actions>
    <action datetime="2019-09-09">
      <text>Introduced in House</text>
    </action>
    <action datetime="2019-09-09" state="REFERRED">
      <text>Referred to the House Committee on Energy and Commerce.</text>
    </action>
    <action datetime="2019-09-10">
      <text>Referred to the Subcommittee on Health.</text>
    </action>
  </actions>
  <committees>
    <committee code="HSIF" name="House Energy and Commerce" subcommittee="" activity="Referral"/>
    <committee code="HSIF14" name="House Energy and Commerce" subcommittee="Health" activity="Referral"/>
  </committees>
  <relatedbills/>
  <subjects>
    <term name="Health"/>
    <term name="Competition and antitrust"/>
    <term name="Digestive and metabolic diseases"/>
    <term name="Drug safety, medical device, and laboratory regulation"/>
    <term name="Licensing and registrations"/>
    <term name="Manufacturing"/>
    <term name="Prescription drugs"/>
  </subjects>
  <amendments/>
  <summary date="2021-09-14T13:53:47Z" status="Introduced in House">Market Access for Generic Insulin Competition or the MAGIC Act 

This bill provides a pathway for the Food and Drug Administration to approve chemically synthesized insulin or an analogue of chemically synthesized insulin as a generic drug under the abbreviated new drug application process.</summary>
</bill>
